Do Analysts Expect Aligos Therapeutics Inc (ALGS) Stock to Rise After It Is Up 12.61% in a Month?

InvestorsObserver is giving Aligos Therapeutics Inc (ALGS) an Analyst Rating Rank of 15, meaning ALGS is ranked higher by analysts than 15% of stocks. The average price target for ALGS is $4.9 and analyst’s rate the stock as a Buy.

Wall Street analysts are rating ALGS a Buy today. Find out what this means to you and get the rest of the rankings on ALGS!

See Full ALGS Report

Why are Analyst Ratings Important?

Though analyst projections should not be your only resource when determining your position on a stock, it can be a very useful tool. Analysts follow sectors/industries in-depth and tend to know how local and global conditions tend to affect demand and prices. Many analysts even participate in conference calls where they can get information to better make sense of the numbers. InvestorsObserver averages the ratings provided by analysts and then ranks their score as a percent against the market. This allows you to compare stocks in a more comprehensive fashion than with the typical buy/sell/hold ranking.

What's Happening With Aligos Therapeutics Inc Stock Today?

Aligos Therapeutics Inc (ALGS) stock is unmoved 0% while the S&P 500 is up 2.4% as of 1:23 PM on Friday, Jun 24. ALGS is flat $0.00 from the previous closing price of $1.34 on volume of 179,542 shares. Over the past year the S&P 500 is lower by -8.90% while ALGS is down -94.82%. ALGS lost -$3.31 per share the over the last 12 months. Click Here to get the full Stock Report for Aligos Therapeutics Inc stock.